Jak1 inhibitor superior to abatacept in head-to-head ra trial

Access through your institution Buy or subscribe In the phase III SELECT-CHOICE trial, the Janus kinase (JAK) inhibitor upadacitinib outperformed the T cell co-stimulation modulator

abatacept for the treatment of rheumatoid arthritis (RA) refractory to biologic DMARDs. Upadacitinib, which selectively targets JAK1, was superior to abatacept with respect to improvements

in disease activity and achievement of remission, but was also associated with more adverse events than was abatacept. SELECT-CHOICE enrolled patients with moderate-to-severe active RA

despite treatment with ≥1 biologic DMARD or who had experienced unacceptable adverse effects from ≥1 biologic DMARD; those with previous exposure to a JAK inhibitor or abatacept were

excluded. “In previous studies, JAK inhibitors have only been compared to adalimumab in patients with an inadequate response to methotrexate. SELECT-CHOICE is the first head-to-head trial in

patients who failed to respond to biologic DMARDs,” adds Rubbert-Roth. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12

print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be

subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

REFERENCES ORIGINAL ARTICLE * Rubbert-Roth, A. et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. _N. Engl. J. Med._ 383, 1511–1521 (2020) Article  CAS  Google Scholar 

RELATED ARTICLES * O’Shea, J. J. & Gadina, M. Selective Janus kinase inhibitors come of age. _Nat. Rev. Rheumatol._ 15, 74–75 (2020) Article  Google Scholar  Download references AUTHOR

INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Rheumatology http://www.nature.com/nrrheum/ Sarah Onuora Authors * Sarah Onuora View author publications You can also search for this

author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Sarah Onuora. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Onuora, S. JAK1

inhibitor superior to abatacept in head-to-head RA trial. _Nat Rev Rheumatol_ 16, 667 (2020). https://doi.org/10.1038/s41584-020-00535-5 Download citation * Published: 27 October 2020 *

Issue Date: December 2020 * DOI: https://doi.org/10.1038/s41584-020-00535-5 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link

Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative